List view / Grid view
Hal V. Barron (born 1962) is an American clinician-scientist and drug developer currently serving as president of research and development at Calico. He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.
Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs. In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.
Barron’s current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 90 papers in peer-reviewed scientific journals. He was a member of the board of directors at Alexza Pharmaceuticals.
Final results from the phase III AVAglio study...
1 June 2013 | By Roche
Final results from the phase III AVAglio study...
Roche announced that the U.S. FDA has approved ACTEMRA...
30 April 2013 | By Roche
Roche announced that the U.S. FDA has approved ACTEMRA...
“The CHMP’s recommendation of Erivedge is encouraging news..."
26 April 2013 | By Roche
“The CHMP’s recommendation of Erivedge is encouraging news..."
The EMA has expanded the approval of Pegasys...
18 March 2013 | By Roche
The EMA has expanded the approval of Pegasys...
Roche announced that the EMA has approved PERJETA (pertuzumab) for…
5 March 2013 | By Roche
Roche announced that the EMA has approved PERJETA (pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC)...
New personalised medicine helped people in Phase III study live…
22 February 2013 | By Roche
New personalised medicine helped people in Phase III study live longer, compared to standard treatment...
Positive results from stage 1 of CLL11...
31 January 2013 | By Roche
Positive results from stage 1 of CLL11...
Roche announced that the US FDA approved a new use…
24 January 2013 | By Roche
Roche announced that the US FDA approved a new use of Avastin...
First medicine approved to treat influenza in infants two weeks…
22 December 2012 | By Roche
First medicine approved to treat influenza in infants two weeks of age and older...
Positive opinion for the use of Perjeta (pertuzumab)...
14 December 2012 | By Roche
Positive opinion for the use of Perjeta (pertuzumab)...
Roche announced results from two studies...
8 December 2012 | By Roche
Roche announced results from two studies...
Roche announced updated survival results from the Phase III CLEOPATRA…
8 December 2012 | By Roche
Roche announced updated survival results from the Phase III CLEOPATRA study...
Results from positive phase III AVAglio study...
17 November 2012 | By Roche
Results from positive phase III AVAglio study...
The continued use of Avastin based therapy beyond first progression…
16 November 2012 | By Roche
The continued use of Avastin based therapy beyond first progression in metastatic colorectal cancer patients leads to survival benefits...
The EC has approved Avastin...
31 October 2012 | By Roche
The EC has approved Avastin...
